Glaukos Corporation $GKOS Stock Position Trimmed by Brown Capital Management LLC

Brown Capital Management LLC decreased its position in Glaukos Corporation (NYSE:GKOS) by 33.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 762,760 shares of the medical instruments supplier’s stock after selling 376,359 shares during the period. Glaukos makes up approximately 2.6% of Brown Capital Management LLC’s investment portfolio, making the stock its 15th largest position. Brown Capital Management LLC’s holdings in Glaukos were worth $62,203,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in GKOS. UMB Bank n.a. grew its holdings in Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 158 shares in the last quarter. AlphaQuest LLC boosted its position in Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after acquiring an additional 633 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Glaukos by 16.2% in the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 136 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Glaukos by 909.7% during the second quarter. Parkside Financial Bank & Trust now owns 1,252 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 1,128 shares during the period. Finally, State of Wyoming raised its stake in shares of Glaukos by 13.1% during the third quarter. State of Wyoming now owns 1,723 shares of the medical instruments supplier’s stock valued at $141,000 after purchasing an additional 199 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. BTIG Research increased their target price on shares of Glaukos from $123.00 to $131.00 and gave the company a “buy” rating in a research report on Wednesday, January 28th. UBS Group raised their price objective on shares of Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. The Goldman Sachs Group restated a “buy” rating and issued a $138.00 price objective on shares of Glaukos in a report on Friday, January 9th. Wells Fargo & Company raised their price objective on shares of Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Glaukos presently has a consensus rating of “Moderate Buy” and an average price target of $132.54.

Glaukos Stock Down 1.6%

Shares of Glaukos stock opened at $117.53 on Tuesday. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $161.78. The company has a market cap of $6.75 billion, a P/E ratio of -76.32 and a beta of 0.70. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average price of $113.61 and a 200 day moving average price of $96.96.

Insider Activity

In other Glaukos news, Director Marc Stapley sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total value of $1,915,650.00. Following the transaction, the director owned 37,449 shares in the company, valued at approximately $4,782,611.79. This represents a 28.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Thomas William Burns sold 186,945 shares of Glaukos stock in a transaction on Friday, January 16th. The shares were sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the sale, the chief executive officer directly owned 153,775 shares of the company’s stock, valued at $17,684,125. This trade represents a 54.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 329,655 shares of company stock valued at $37,752,234 in the last three months. 6.40% of the stock is currently owned by insiders.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.